Facebook Linkedin RSS Twitter Youtube
Home 2024

Amyloidosis

Bridgebio’s Attruby, to Treat Heart Condition ATTR-CM, Receives FDA Approval
Drug Discovery

Bridgebio’s Attruby, to Treat Heart Condition ATTR-CM, Receives FDA Approval

Challenges in Biologics R&D
Bioprocessing

Challenges in Biologics R&D

Gene Therapy Pioneers Share Genome Editing Insights at Chardan Conference
Drug Discovery

Gene Therapy Pioneers Share Genome Editing Insights at Chardan Conference

Combatting Therapeutic-Protein Aggregation
Bioprocessing

Combatting Therapeutic-Protein Aggregation

Therapeutic Advances Using In Vivo CRISPR Genome Editing
Genome Editing

Therapeutic Advances Using In Vivo CRISPR Genome Editing

“GEN Edge Live”: Analyzing the Latest Milestones in Genome Editing
GEN Edge

“GEN Edge Live”: Analyzing the Latest Milestones in Genome Editing

Heart of the Deal: Prothena Executives on the $1.2B Sale of ATTR Amyloidosis Candidate to Novo Nordisk
Drug Discovery

Heart of the Deal: Prothena Executives on the $1.2B Sale of ATTR Amyloidosis Candidate to Novo Nordisk

“New Era of Medicine”: Researchers Publish First Positive Clinical Data for In Vivo Genome Editing in Humans
Genome Editing

“New Era of Medicine”: Researchers Publish First Positive Clinical Data for In Vivo Genome Editing in Humans

Antibody Targets Protein Misfolding with High Precision
BioPerspectives

Antibody Targets Protein Misfolding with High Precision

Tekmira Wins $5M Milestone from Alnylam as Patisiran Enters Phase III
News

Tekmira Wins $5M Milestone from Alnylam as Patisiran Enters Phase III

12Page 1 of 2
Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.